Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 435 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
435 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (including classical, atypical, exon 20 insertion, and resistance mutations) and/or HER2 kinase domain mutations who have received standard therapies, testing the investigational oral agent BH-30643, a mutant-selective OMNI-EGFR inhibitor targeting a broad spectrum of EGFR and HER2 mutations. Patients must have measurable disease, good performance status, and no significant comorbidities or prior ILD.
ClinicalTrials.gov ID: NCT06706076
HealthScout AI summary: Adults with advanced unresectable or metastatic melanoma (non-uveal/mucosal), head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, or classical Hodgkin lymphoma who have progressed on prior PD-1/PD-L1 therapy are eligible to receive CTX-8371, an investigational bispecific antibody targeting PD-1 and PD-L1 designed to overcome checkpoint inhibitor resistance, as monotherapy.
ClinicalTrials.gov ID: NCT06150664
HealthScout AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.
ClinicalTrials.gov ID: NCT06747585
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors expressing CEACAM5—including colorectal, non-small cell lung, or gastric cancer—who have progressed after standard therapies, to receive investigational BMS-986490 (a first-in-class targeted agent for CEACAM5-expressing malignancies) alone or combined with bevacizumab. Key exclusions include prior anti-CEACAM5 therapy or significant pulmonary toxicity.
ClinicalTrials.gov ID: NCT06730750
HealthScout AI summary: This trial enrolls adults with advanced solid tumors, including NSCLC, harboring SMARCA4 (BRG1) alterations who have no standard treatment options and ECOG 0-1, and treats them with LY4050784, an investigational oral selective SMARCA2/BRM ATPase inhibitor targeting cancers with SMARCA4 loss of function.
ClinicalTrials.gov ID: NCT06561685
HealthScout AI summary: Eligible patients have advanced, unresectable, or metastatic solid tumors of multiple types that are refractory to standard therapy and have a tumor accessible for intratumoral injection or biopsy. This trial evaluates the investigational oncolytic immunotherapy VET3-TGI (a vaccinia-derived agent engineered to kill tumor cells and modulate the tumor microenvironment via CXCR3, IL-12, and TGF-β inhibition) given by intratumoral or intravenous administration, alone or with pembrolizumab.
ClinicalTrials.gov ID: NCT06444815
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.
ClinicalTrials.gov ID: NCT06781983
HealthScout AI summary: This trial enrolls adults with recurrent or metastatic non-small cell lung cancer who have progressed after prior chemotherapy and PD-1/PD-L1 inhibitor therapy, testing the combination of nivolumab with PBF-1129, an investigational oral adenosine A2B receptor antagonist targeting the tumor microenvironment to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05234307
HealthScout AI summary: This trial enrolls adults with advanced EGFR-mutant NSCLC (Ex19del or L858R, with or without T790M) who have progressed on prior osimertinib, and evaluates the safety and dosing of the investigational agent minnelide (an oral prodrug of triptolide, which inhibits HSP72 and other pathways) in combination with standard osimertinib.
ClinicalTrials.gov ID: NCT05166616
HealthScout AI summary: This trial enrolls adults with advanced solid tumors, including patients with RAS-altered tumors, previously treated advanced/metastatic renal cell carcinoma, and KRAS G12C-mutant cancers, to evaluate KO-2806, a next-generation farnesyltransferase inhibitor, as monotherapy or in combination with cabozantinib or adagrasib. KO-2806 targets RAS and other farnesylated proteins to inhibit oncogenic signaling and overcome resistance mechanisms.
ClinicalTrials.gov ID: NCT06026410